Phibro Animal Health (NASDAQ:PAHC) Trading Down 4.5% – Should You Sell?

Phibro Animal Health Corporation (NASDAQ:PAHC) dropped 4.5% during mid-day trading on Wednesday . The stock traded as low as $56.35 and last traded at $56.3870. Approximately 28,549 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 273,254 shares. The stock had previously closed at $59.02.

Analyst Upgrades and Downgrades

PAHC has been the topic of several recent research reports. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Citigroup started coverage on Phibro Animal Health in a research report on Wednesday. They set a “neutral” rating and a $62.00 price objective for the company. Finally, Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $42.40.

Phibro Animal Health Stock Performance

The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The company has a 50-day moving average price of $52.93 and a 200-day moving average price of $44.82. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of 24.94, a P/E/G ratio of 0.91 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th were given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Wednesday, March 4th. Phibro Animal Health’s dividend payout ratio is 21.33%.

Insiders Place Their Bets

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $52.52, for a total value of $369,740.80. Following the completion of the sale, the chief executive officer directly owned 73,320 shares in the company, valued at $3,850,766.40. This represents a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 305,057 shares of company stock valued at $14,804,434 in the last three months. Corporate insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently added to or reduced their stakes in PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after purchasing an additional 546 shares during the period. Millennium Management LLC lifted its position in Phibro Animal Health by 74.3% in the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after purchasing an additional 154,281 shares during the period. Jane Street Group LLC lifted its position in Phibro Animal Health by 65.3% in the first quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock worth $724,000 after purchasing an additional 13,404 shares during the period. Cetera Investment Advisers lifted its position in Phibro Animal Health by 63.0% in the second quarter. Cetera Investment Advisers now owns 18,830 shares of the company’s stock worth $481,000 after purchasing an additional 7,280 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after purchasing an additional 363 shares during the period. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.